NEW YORK (GenomeWeb News) – Agilent Technologies today said that its board of directors has authorized a new share repurchase program, which will become effective following the completion of its existing $1 billion share repurchase program.

The firm didn't say how much it expects to spend on the new repurchase program but stated that the goal is to "reduce or eliminate dilution resulting from issuances of stock under the company's employee equity incentive programs to maintain a share count of approximately 335 million diluted shares."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.